These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 27621622)
41. Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Kramer-Hämmerle S; Rothenaigner I; Wolff H; Bell JE; Brack-Werner R Virus Res; 2005 Aug; 111(2):194-213. PubMed ID: 15885841 [TBL] [Abstract][Full Text] [Related]
42. Molecular characterization and hormonal regulation of tissue inhibitor of metalloproteinase 1 in goat ovarian granulosa cells. Peng JY; Han P; Xin HY; Ji SY; Gao KX; An XP; Cao BY Domest Anim Endocrinol; 2015 Jul; 52():1-10. PubMed ID: 25700266 [TBL] [Abstract][Full Text] [Related]
43. Construction, gene delivery, and expression of DNA tethered nanoparticles. Prow T; Smith JN; Grebe R; Salazar JH; Wang N; Kotov N; Lutty G; Leary J Mol Vis; 2006 May; 12():606-15. PubMed ID: 16760897 [TBL] [Abstract][Full Text] [Related]
44. Expression of CHRFAM7A and CHRNA7 in neuronal cells and postmortem brain of HIV-infected patients: considerations for HIV-associated neurocognitive disorder. Ramos FM; Delgado-Vélez M; Ortiz ÁL; Báez-Pagán CA; Quesada O; Lasalde-Dominicci JA J Neurovirol; 2016 Jun; 22(3):327-35. PubMed ID: 26567012 [TBL] [Abstract][Full Text] [Related]
45. Advancements in nano-enabled therapeutics for neuroHIV management. Kaushik A; Jayant RD; Nair M Int J Nanomedicine; 2016; 11():4317-25. PubMed ID: 27621624 [TBL] [Abstract][Full Text] [Related]
46. Directing the Antiretroviral Drugs to the Brain Reservoir: A Nanoformulation Approach for NeuroAIDS. Nabi B; Rehman S; Pottoo FH; Baboota S; Ali J Curr Drug Metab; 2021; 22(4):280-286. PubMed ID: 32964821 [TBL] [Abstract][Full Text] [Related]
48. Coagulation imbalance and neurocognitive functioning in older HIV-positive adults on suppressive antiretroviral therapy. Montoya JL; Iudicello J; Oppenheim HA; Fazeli PL; Potter M; Ma Q; Mills PJ; Ellis RJ; Grant I; Letendre SL; Moore DJ; AIDS; 2017 Mar; 31(6):787-795. PubMed ID: 28099190 [TBL] [Abstract][Full Text] [Related]
49. Development of an in vitro blood-brain barrier model to study molecular neuropathogenesis and neurovirologic disorders induced by human immunodeficiency virus type 1 infection. Mukhtar M; Pomerantz RJ J Hum Virol; 2000; 3(6):324-34. PubMed ID: 11100913 [TBL] [Abstract][Full Text] [Related]
51. Regulation of ABC membrane transporters in glial cells: relevance to the pharmacotherapy of brain HIV-1 infection. Ronaldson PT; Persidsky Y; Bendayan R Glia; 2008 Dec; 56(16):1711-35. PubMed ID: 18649402 [TBL] [Abstract][Full Text] [Related]
52. Neurologic disease in HIV-infected children and the impact of combination antiretroviral therapy. Crowell CS; Malee KM; Yogev R; Muller WJ Rev Med Virol; 2014 Sep; 24(5):316-31. PubMed ID: 24806816 [TBL] [Abstract][Full Text] [Related]
53. Nanoformulation of antiretroviral drugs enhances their penetration across the blood brain barrier in mice. Fiandra L; Colombo M; Mazzucchelli S; Truffi M; Santini B; Allevi R; Nebuloni M; Capetti A; Rizzardini G; Prosperi D; Corsi F Nanomedicine; 2015 Aug; 11(6):1387-97. PubMed ID: 25839392 [TBL] [Abstract][Full Text] [Related]
54. Amyloid beta accumulation in HIV-1-infected brain: The role of the blood brain barrier. András IE; Toborek M IUBMB Life; 2013 Jan; 65(1):43-9. PubMed ID: 23225609 [TBL] [Abstract][Full Text] [Related]